ACE2 and pulmonary arterial hypertension: Therefore, genetically engineered approaches which upregulate ACE2 expression or activity and/or pharmacological ACE2 activators and recombinant human ACE2 may represent a novel therapeutic strategy in the management of PAH patients (Figure 2).